What, Me Worry? ROS1 patients find calm by managing stressors specific to ROS1 cancer


This article by Joyce Hoelting first appeared in the Fall 2021 ROS1derings (newsletter of The ROS1ders).  If you’d like to receive future editions of our newsletter by email, please subscribe to our blog by providing your email on our Contact Form. ———————————— The more researchers learn about cancer, the more cancer patients can learn about … Continue reading What, Me Worry? ROS1 patients find calm by managing stressors specific to ROS1 cancer

The Importance of Research and Clinical Trials


November is Lung Cancer Awareness Month.  Today we’re sharing the story of a ROS1+ lung cancer patient and how she’s benefitted from research. This article first appeared in the Fall 2021 ROS1derings (newsletter of The ROS1ders).  If you’d like to receive future editions of our newsletter by email, please subscribe to our blog by providing … Continue reading The Importance of Research and Clinical Trials

AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021


The Spanish Association of Lung Cancer Patients (AEACaP) and Lung Cancer Europe (LuCE) will be hosting the webinar “ROS-1 Lung Cancer Patients” on Friday, March 26th, 2021 at 18.00 Central European Time (10 am Pacific Time). The event will provide information about the ROS1 biomarker and treatment in lung cancer, as well as research and … Continue reading AEACaP and Lung Cancer Europe (LuCE) host “ROS-1 Lung Cancer Patients” webinar on 26-Mar-2021

The ROS1ders publishes report to move ROS1+ cancer research forward


Today The ROS1ders published a white paper titled, “Sustaining and Accelerating Research for ROS1 Cancer.” The document summarizes key themes and subsequent discussions from two ROS1ders Research Roundtable virtual meetings, which brought together members of The ROS1ders with leading ROS1 clinicians and researchers. The report also offers a “Call to Action” to help move ROS1 … Continue reading The ROS1ders publishes report to move ROS1+ cancer research forward

Calling all ROS1ders! Please help Australians access Entrectinib


For the first time, Australian ROS1+ lung cancer patients may have affordable access to Entrectnib. Currently, ROS1 patients cannot get access to Entrectnib outside of a clinical trial. We need the help of ROS1ders to make it happen. From 1 February 2020, Australian who have ROS1+ lung cancer may be able to purchase the medication … Continue reading Calling all ROS1ders! Please help Australians access Entrectinib

ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!


Lung Cancer Canada (LCC) is seeking ROS1 positive non-small cell lung cancer (NSCLC) patients and caregivers who have past or present treatment experience with ENTRECTINIB to share their experiences. This information will be used to provide patient/caregiver input that will help in determining accessibility of this drug for lung cancer patients in Canada. LCC and … Continue reading ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!